Pyrophosphoric Acid

Pyrophosphoric Acid

SCHEMBL2935409

Nc1nc2c(c(=O)[nH]1)N=C(CO)CN2.O=P(O)(O)OP(=O)(O)O

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
RGS12 O14924 1/20 0.49
LMNA P02545 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAPT P10636 1/20 0.49
CASP1 P29466 1/20 0.49
BLM P54132 1/20 0.49
CASP7 P55210 1/20 0.49
GNAI1 P63096 1/20 0.49
KMT2A Q03164 1/20 0.49
HIF1A Q16665 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HPRT1 P00492 5/20 0.35
DHFR P00374 5/20 0.33
NOS1 P29475 3/20 0.33
POLB P06746 2/20 0.33
PNP P00491 1/20 0.33
POLG P54098 2/20 0.33
POLA1 P09884 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL230712 0.90 CASP7 (0.54) KDM4EMEN1RGS12LMNACYP3A4
SCHEMBL3721701 0.85 KDM4E (0.46) KDM4EMEN1RGS12LMNACYP3A4
SCHEMBL25433714 0.84 CASP7 (0.49) KDM4EMEN1RGS12LMNACYP3A4
Pyrophosphoric Acid SCHEMBL381155 0.79 KDM4E (0.30) KDM4EMEN1RGS12LMNACYP3A4
7,8-Dihydropteroate SCHEMBL25432562 0.78 KDM4E (0.41) KDM4EMEN1RGS12LMNACYP3A4
SCHEMBL9152033 0.74 CASP7 (0.52) KDM4EMEN1RGS12LMNACYP3A4
SCHEMBL381157 0.74
SCHEMBL31338610 0.72 CASP7 (0.48) KDM4EMEN1RGS12LMNACYP3A4
SCHEMBL1533829 0.71 KDM4E (0.45) KDM4EMEN1RGS12LMNACYP3A4
SCHEMBL7077068 0.71 CASP7 (0.58) KDM4EMEN1RGS12LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021148-A1 METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2026-01-22 US disclosed
US-20250207207-A1 TAXONOMIC SIGNATURES AND METHODS OF DETERMINING THE SAME BAYLOR COLLEGE OF MEDICINE (US) 2025-06-26 US disclosed
US-12318413-B2 Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-06-03 US disclosed
US-12310996-B2 Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-05-27 US disclosed
CN-118660711-A Methods and compositions for predicting cancer survival and CAR T cytotoxicity 纪念斯隆-凯特琳癌症中心 2024-09-17 CN disclosed
EP-4426324-A1 METHODS AND COMPOSITIONS FOR PREDICTING CANCER SURVIVAL AND CAR T CELL TOXICITY Memorial Sloan Kettering Cancer Center (US) 2024-09-11 EP disclosed
US-20240293481-A1 METHODS AND COMPOSITIONS FOR PREDICTING CANCER SURVIVAL AND CAR T CELL TOXICITY MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2024-09-05 US disclosed
US-20240173361-A1 METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-05-30 US disclosed
CN-114286858-B Folic acid producing strain, and preparation and application thereof 赤峰制药股份有限公司 2024-05-28 CN disclosed
US-20230233620-A1 HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES Kanvas Biosciences, Inc. 2023-07-27 US disclosed
CN-116096881-A Microorganism producing 5-methyl folate 赤峰制药股份有限公司 2023-05-09 CN disclosed
US-20230109343-A1 METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-04-06 US disclosed
US-11395838-B2 Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-07-26 US disclosed
EP-4017959-A1 FOLATE PRODUCING STRAIN AND THE PREPARATION AND APPLICATION THEREOF Chifeng Pharmaceutical Co., Ltd (CN) 2022-06-29 EP disclosed
CN-114286858-A Folic acid producing strain and preparation and application thereof 赤峰制药股份有限公司 2022-04-05 CN disclosed
US-20220081708-A1 DIAGNOSIS AND TREATMENT OF DYSBIOSIS-ASSOCIATED WITH NEC Infinant Health, Inc 2022-03-17 US disclosed
US-20200129569-A1 METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2020-04-30 US disclosed
CN-105137086-A Kit and test strip for detecting sulfonamides and use thereof UNIV CHINA AGRICULTURAL 2015-12-09 CN disclosed
CN-105018406-A Recombinant Escherichia coli for producing protein capable of detecting sulfonamide as well as construction method and application of recombinant Escherichia coli UNIV CHINA AGRICULTURAL 2015-11-04 CN disclosed
EP-2230312-A1 Probe compound for detecting and isolating enzymes and means and methods using the same Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2010-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021148-A1 METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME PDCD1, CD274, PDCD1LG2 KDM4E 254/4885MEN1 1246/4885RGS12 3532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.